Millennium reiterated at market outperform by JMP

JMP Securities analyst Charles Duncan reiterated Millennium Pharmaceuticals, Inc. at market outperform. Millennium reported fourth-quarter and fiscal-year 2005 earnings that met the analyst's and the Street's expectations. Velcade sales are anticipated to be considerably challenged by Revlimid. Shares of the Cambridge, Mass., pharmaceutical company were up 7 cents, or 0.69%, at $10.28 on volume of 3,372,356 shares versus the three-month running average of 4,306,080 shares. (Nasdaq: MLNM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.